Abstract: There is provided a serum- or plasma-separating composition capable of maintaining stable blood separation performance over a prolonged period even if subjected to a sterilization step during production or to prolonged storage. The serum- or plasma-separating composition comprises a resin composition having fluidity at normal temperature, a silica fine powder, and an amide-based compound represented by the following formula (1): wherein R3 is an alkyl group having 1 to 4 carbon atoms; and R1 and R2 are independently a hydrogen atom or a linear or branched alkyl group having 1 to 8 carbon atoms.

Abstract: A sterile solution product bag includes sterilization grade filter integrated directly into the product bag such that microbial and particulate matter filtration can be performed using the filter directly at the point of fill. The filter can include a hollow fiber filter membrane contained in a stem connected to a bladder of the product bag.

Abstract: An end cap which is prepared for being fastened, especially attached, to an especially pipe socket-type connecting port of a cartridge-shaped receptacle and in a mounted state serves for sealing the connecting port, including a top surface portion, a shell surface portion being connected, especially perpendicularly and cylindrically, to the top surface portion, and a flange portion connected to the shell surface portion, the flange portion including and/or forming a sealing portion, by which the end cap can be fixed and sealed to the cartridge-shaped receptacle, and a predetermined breaking/tearing portion, at which the end cap tears and/or breaks in a predefined manner when the end cap is removed from the cartridge-shaped receptacle.

Abstract: Arrangements are provided for “smart” functionality such as for tracking medication use to determine adherence, without requiring smart containers therefor. A bin is provided for receiving used/empty containers, packaging, or other discarded material incidental to the use of the medication. Sensors generate signals when the material is deposited within the bin, and a processor determines whether those signals correspond with the incidental material of interest. The processor also may identify when signals correspond with other, spurious material deposited in the bin. Responsive to a positive correspondence, a contextual event such as deposition of a used vial is stored, displayed, communicated, and/or otherwise registered. Contextual events, times therefor, lack of same, etc. are considered to provide authenticated determinations of adherence to a medication regimen.

Abstract: Patients with substance abuse problems may be prescribed regular medication that dulls the positive effects of the substance. However, one of the largest challenges for substance abuse patients is that many do not regularly take their medication as they want to experience the high of the substance. Accordingly, systems and methods have been developed for medication sessions that distract the patient from taking the medicine by incorporating the reminder and other med actions in close temporal proximity.

Abstract: Polymerizable dental compositions comprising a redox initiator system is disclosed. The redox initiator system comprises a photolabile transition metal complex that photolyzes and initiates the redox cycle.

Abstract: The present invention relates to a composition for a hydrogel sheet including a cellulose ether, a gelling agent, and a gelling promoter, a hydrogel sheet prepared therefrom, and a method of preparing the hydrogel sheet. According to the present invention, the composition for a hydrogel sheet can be used to prepare a hydrogel sheet capable of maintaining the shape thereof without a support by limiting a type of the gelling agent and/or a viscosity of the cellulose ether included in the composition.

Abstract: The instant invention relates to a composition for caring for and/or making up keratin materials comprising, in a physiologically acceptable medium, at least one microcapsule containing at least one encapsulated releasable material(s) said microcapsule comprising at least one core and at least one layered coating surrounding said core, and said encapsulated material(s) being at least one reflective particle, and being only released from said microcapsule(s) when said composition is applied onto a keratin material, such as keratin fibers or skin. The invention further relates to a cosmetic process for caring for and/or making up keratinic materials, comprising application on said keratinic materials in particular on the skin of a composition as defined above.

Abstract: Disclosed are UV-protective compositions comprising swelled polymer matrix macroparticles comprising a thermoplastic polymer swelled with at least one swelling agent, and a plurality of nanoparticles of an inorganic UV-protective agent comprising at least one solid inorganic crystal and a dispersant associated with the crystal, wherein the inorganic nanoparticles are dispersed and embedded in the swelled polymer matrix macroparticles. Method of preparation and uses of such compositions are also provided.

Abstract: The present invention relates to a core-shell type polymer particle including a shell part composed of an amphoteric polymer (A) and a core part composed of a hydrophobic polymer (B).

Abstract: A composition for preventing hair loss or promoting hair growth comprising Decanal or pharmaceutically acceptable salt thereof as an active ingredient is provided. In particular, the composition relates to a quasi-drug, a cosmetic composition, a health functional food composition, and a pharmaceutical composition for preventing hair loss or promoting hair growth, which exhibits an excellent and stable effect on hair growth and hair growth, even while comprising a natural compound which has no side effect even in long-term administration in a chronic disease as an active ingredient.

Abstract: The present disclosure relates to leave-on hair styling compositions comprising: (a) at least one sugar alcohol: (b) inulin; (c) sclerotium gum; (d) at least one water-soluble solvent; and (e) water. The leave-on hair styling compositions provide excellent hair styling benefits without requiring synthetic film-forming polymers and/or silicones. In particular, the leave-on hair styling compositions are useful for imparting durable styling or shaping benefits, providing volume and fullness, and imparting frizz control to hair.

Abstract: Compositions and methods of manufacture for an extended time-release fragrance comprising volatile organic compounds. A composition of the disclosure includes an effective amount of a volatile organic compound for providing a fragrance that can be sensed by a user and fractionated coconut oil comprising caprylic acid and capric acid.

Abstract: A method for styling hair comprising: —applying to hair a hair treatment composition comprising from 4 to 25 wt % a citric or aconitic acid and having a pH of from 1 to 3; —leaving the product on the hair for from 5 to 90 minutes; —rinsing the product from the hair; and —styling.

Abstract: Cosmetic composition comprising a salicylic acid compound The invention relates to a composition in the form of an oil-in-water emulsion comprising: —a fatty acid ester of polyethylene glycol; —a C16-C22 fatty acid ester of glycerol; —a polycondensate of ethylene oxide and of propylene oxide constituted of polyethylene glycol and polypropylene glycol blocks; —an at least partially neutralized acrylic acid homopolymer; —a 2-acrylamido-2-methylpropanesulfonic acid polymer; —a salicylic acid compound. The composition has good stability, in particular after 15 days of storage at 55° C. Use for caring for and making up keratin materials.

Abstract: This invention relates to the use of polycarboxylic acid compounds, aqueous compositions comprising the same, cosmetic compositions comprising the same, in particular, hair care compositions, and their use for the treatment of hair, and a process for the treatment of hair comprising the use of said cosmetic compositions.

Abstract: The present disclosure relates to agents for the oxidative coloring of keratinic fibers, which are characterized in hat they contain derivatives of anisole as novel developer molecules.

Abstract: The present invention relates to a composition comprising one or more quaternary ester ammonium compounds (a), one or more amidoamine compounds (b), wherein the weight ratio between the one or more quaternary ester ammonium compounds (a) and the one or more amidoamine compounds (b) is within a range of 1:5 to 5:1, and one or more fatty alcohols (c). The present invention also relates to a composition that is solid at room temperature, to a hair conditioner composition and to a method to prepare the hair conditioner composition by dispersing the solid composition in water at moderate temperatures.

Abstract: This invention relates to oral care compositions comprising arginine or lysine, zinc citrate and zinc oxide, fluoride source, and a silica abrasive which exhibits an acid pH when measured as an aqueous slurry as well as to methods of using and of making these compositions.

Abstract: This invention relates to an antimicrobial composition, especially one which provides synergistic anti-dandruff efficacy. This is achieved through a judicious combination of anti-dandruff agent zinc pyrithione and a piperazine compound of specific type. These compositions can be delivered through very many different types of personal care products e.g. shampoo or conditioner.

Abstract: The present invention relates to a composition for improving scalp condition and/or promoting hair restoration containing soyasaponin or a derivative thereof, which can be widely used as an external skin preparation for improving scalp condition and/or promoting hair growth and hair restoration, a cosmetic composition or a pharmaceutical composition, as the composition has high stability for skin without side effects, improves a scalp condition, and is effective in promoting hair growth and/or preventing hair loss by activating stem cells.

Abstract: Process for the treatment of, e.g., visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing, in a physiologically acceptable medium, at least 5% by weight of one or more surfactants comprising at least one alkyl chain having from 6 to 16 carbon atoms.

Abstract: A skin smoothing composition that has from about 0.5 to about 10%, by weight, of an interpenetrating polymer that is a co-polymer of polyurethane and a polyacrylic polymer. The composition further contains from about 0.1% to about 5%, by weight, of a thickener made from homopolymers of acrylic acid crosslinked with a cross linker selected from the group consisting of an allyl ether pentaerythritol, allyl ether of sucrose, allyl ether of propylene and mixtures thereof and from about 10 to 98% water.

Abstract: The present invention relates to a composition comprising particles of a polymer that is surface-stabilized with a stabilizer, the polymer of the particles being a C1-C4 alkyl (meth)acrylate polymer; the stabilizer being an isobornyl (meth)acrylate polymer chosen from isobornyl (meth)acrylate homopolymer and statistical copolymers of isobornyl (meth)acrylate and of C1-C4 alkyl (meth)acrylate present in an isobornyl (meth)acrylate/C1-C4 alkyl (meth)acrylate weight ratio of greater than 4, at least one hydrocarbon-based oil and at least one mineral thickener chosen from optionally modified clays and optionally modified silicas, or mixtures thereof. The invention also relates to a process for making up and/or caring for keratin materials, in which said composition is applied.

Abstract: Process for treating keratin fibres with an ethylenicpolymer bearing a maleic anhydride group and a polyol The invention relates to a cosmetic process for treating keratin fibres, comprising the application to the keratin fibres of a mixture of a maleic anhydride ethylenic polymer, a liposoluble polyol and an amine catalyst; said maleic anhydride ethylenic polymer being obtained by polymerization of: (a) 25% to 95% by weight, relative to the total weight of monomers, of an ethylenic monomer bearing an at least C8 linear or branched alkyl group; (b) 5% to 25% by weight of maleic anhydride; (c) 0% to 50% by weight of additional (meth)acrylate monomer; and a step of heating the keratin fibres to a temperature ranging from 90° C. to 250° C. The invention also relates to the crosslinked polymer obtained by reacting said ethylenic polymer with said liposoluble polyol. The treated keratin fibres have good water-resistant fixing properties.

Abstract: A robust sunscreen composition is disclosed herein comprising a water soluble polymer and a water insoluble film former providing a synergistic effect in SPF retention and critical wavelength after immersion in water, salt water, and chlorinated water. The water soluble polymer comprises poloxamer 338 (and) PPG-12/SMDI copolymer, poloxamer 407 (and) PPG-12/SMDI copolymer, or a combination thereof.

Abstract: Cosmetic compositions for temporarily deforming keratinic fibers, cosmetic products, and methods for temporarily deforming keratinic fibers are provided herein. In one embodiment, a cosmetic composition for temporarily deforming keratinic fibers includes at least one uncrosslinked anionic polymer, at least one uncrosslinked cationic polymer, and water in a total amount of from about 80 to about 98% by weight, in relation to the total weight of the cosmetic composition.

Abstract: The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of one or more of Butyrospermum parkii (shea butter), PEG-50 shea butter, glycerin, Helianthus annuus (sunflower) seed oil, Prunus armeniaca (apricot) kernel oil, acrylates copolymer, sodium lauryl sulfate, lauramidopropyl betaine, sodium methyl cocoyl taurate, glycerin, and polyquaternium-7.

Abstract: The invention relates to an emulsifier-free, skin conditioning cosmetic or dermatological preparation which contains active ingredients.

Abstract: Compositions, methods, and kits for cleansing, moisturizing, soothing, cooling, such as those, for example, that may be used to cleanse, moisturize, soothe, and cool the body or portions thereof.

Abstract: Disclosed is a topical skin care formulation comprising water, kaolin, glycerin, lactobacillus ferment, Helianthus annuus seed extract, and Terminalia ferdinandiana fruit extract.

Abstract: Implementations of a topical homeopathic formulation may include an active portion including a plurality of active ingredients and a base including a plurality of inactive ingredients. The plurality of active ingredients may include one of tinctures and homeopathic preparations of Apis mellifica, Arnica montana, Atropa belladonna, Bellis perennis, Bryonia alba, Cactus grandifloras, Caulophyllum thalictroides, Cimicifuga racemose, Citrullus colocynthis, Cyclamen europaeum, Gelsemium Sempervirens, Gnaphalium polycephalum, Jonesia asoca, Juniperus Sabina, Kali carbonicum, Lilium tigrinum, Rhamnus californica, Tilia europaea, Viburnum opulus, and any combination thereof.

Abstract: A method of treating pain, e.g., acute post-operative pain, by intravenously administering to a human patient(s) a dose of tramadol of about 45 mg to about 80 mg, based on tramadol hydrochloride, together with an intravenous dose of acetaminophen in an amount from about 500 mg to about 1000 mg, about every 6 hours.

Abstract: A cannabis infused sweetener comprising cannabis oil; at least one emulsifying agent selected from the group consisting of xanthan gum, guar gum, lecithin, carrageen, monoglycerides, natural emulsifiers and organic emulsifiers that are safe for ingestion by humans; and a sweetener; and a cannabis infused elixir comprising cannabis oil; at least one emulsifying agent; a sweetener and flavoring extracts or fruit syrups; both the sweeteners and the elixirs are bio-available, fast acting and highly metabolizable.

Abstract: The present invention is directed to epinephrine spray formulations. The present invention is further directed to methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatments.

Abstract: Aerosol solution compositions intended for use with a pressurized metered dose inhaler, comprising glycopyrronium bromide and formoterol, or a salt thereof or a solvate of said salt, optionally in combination with one or more additional active ingredients, and stabilized by a selected amount of a mineral acid, exhibit improved stability when contained in a can internally coated by a resin comprising a fluorinated ethylene propylene (FEP) polymer.

Abstract: Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.

Abstract: Compositions and methods for inducing immune tolerance to proteins and subsequence administration of the proteins are disclosed. Compositions comprise proteins complexed with liposomes comprising PS and PC, wherein at least part of the PS is present as lyso-PS.

Abstract: The present invention relates to: a pharmaceutical composition for preventing or treating ischemic diseases, containing liposomes into which vascular endothelial growth factor (VEGF)-derived peptides are loaded; a method for treating ischemic diseases, comprising the step of administering the pharmaceutical composition to an individual suspected of having an ischemic disease; a use of the liposomes; and a kit for evaluating, using the liposomes, the amount of liposomes, into which VEGF-derived peptides are loaded, delivered to ischemic lesions and of loaded materials released and absorbed.

Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.

Abstract: This disclosure relates to polymersomes comprising a crosslinked polymer and their use as drug delivery vehicles. Specifically, polymersomes comprising a polymer of Formula I: wherein each R is independently C1-6 alkyl; and n is an integer between 1 and 50.

Abstract: A composition for use in the treatment of fistula, the composition comprising activated carbon.

Abstract: Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.

Abstract: The invention relates to processes for dry powder blending. Specifically the invention relates to dry powder blending of pharmaceutical and non-pharmaceutical solid particulate matter and powders. More specifically the invention relates to dry powder blending of microparticles, and to dry powder blends for use as pharmaceuticals. In particular, the present invention relates to a process of preparing a dry microparticulate powder blend comprising one or more micronized active pharmaceutical ingredient(s) (API) and optionally, one or more micronized or non-micronized pharmaceutically acceptable carrier(s) and/or excipient(s), wherein the process comprises the steps of ‘pulsating blending’ of the micronized active pharmaceutical ingredient(s) and the pharmaceutically acceptable carrier(s) and/or excipient(s).

Abstract: The present invention provides for method of improving flowability and loose bulk density of functionalized natural- and/or synthetic calcium carbonate comprising material, to the use of such improved material in ready to use granules and thereof produced dispersible dosage forms.

Abstract: Disclosed is a preparation method for an azacitidine for injection, wherein each injection vial of azacitidine for injection contains 100 mg of azacitidine and 100 mg of mannitol. The preparation method comprises the steps of measuring 80% of the total volume of water for injection at a temperature of 2-6° C.; adding mannitol, and stirring to completely dissolved at a temperature of 2-6° C.; adding azacitidine, stirring to completely dissolved at a temperature of 2-6° C. to obtain an azacitidine solution for injection; filling each injection vial with 23 ml azacitidine solution for injection after filtration; freeze-drying at a preset temperature; and stoppering, capping and packaging after nitrogen filling. The preparation method has the advantages of a simple process, low energy consumption, high production efficiency and stable product quality.

Abstract: The present invention provides a process for preparing enterically-coated lyospheres comprising a therapeutic agent comprising: a.) providing lyospheres comprising the therapeutic agent; b.) coating said lyospheres with an enteric polymer coating composition; and c.) isolating said enterically-coated lyospheres. In other embodiments, the invention provides dosage forms comprising a lyosphere comprising an effective amount of a therapeutic agent and an enteric polymer coating. In some embodiments, the therapeutic agent in the process or dosage form is a polypeptide, a protein, a peptide, a lipopeptide, a glycoprotein, a fusion protein, a protein conjugate, a cytokine, an enzyme, an antibody, an oligonucleotide, a vaccine vector, small molecule, a live virus, an inactivated virus, a virus-like particle, a viral protein subunit, an adjuvant, microbiome, a prebiotic, a probiotic, or an ectobiotic.

Abstract: Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Abstract: The invention provides pH- or redox-responsive and charge-neutral polymeric nanogels that stably encapsulate a biomolecule at one pH or redox condition and then release it at a different pH or redox condition, and compositions and methods of preparation and use thereof.

Abstract: A flexible body comprises a polymer film having a first surface and an opposing second surface. The polymer film has a plurality of apertures extending from the first surface to the second surface and a plurality of raised lips protruding from the first surface such that each of the plurality of apertures is surrounded by one of the plurality of raised lips. A method of producing a polymer film comprises placing a polymer solution into a one sided mold having a plurality of protrusions extending from a bottom of the mold wherein the polymer solution is characterized by a viscosity that inhibits the unaided flow of the polymer throughout the mold; urging the polymer solution around each of the plurality of protrusions; and solidifying the polymer solution.